FibroScHot – Impact of increased praziquantel frequency on childhood fibrosis in persistent schistosomiasis morbidity hotspots

fibro

Team (UK)

 Project Lead: Dr Shona Wilson, Cambridge University

Co-Principle Investigator: Professor Joanne P. Webster, Royal Veterinary College

Co-Principle Investigator: Dr Martin Walker, Royal Veterinary College

Co-Principle Investigator: Professor Matt Berriman, Wellcome Trust Sanger Institute

Senior Scientist: Dr Elsa Leger, Royal Veterinary College

Student Mentor: Dr James Cotton, Wellcome Trust Sanger Institute

 

Gastrointestinal schistosomiasis caused by Schistosoma mansoni is a devastating Neglected Tropical Disease (NTD). Without control and disease management strategies, sufferers with the manifestation of periportal fibrosis can develop portal hypertension, in its severest form causing death through haematemesis. Mass Drug Administration (MDA) of the safe and efficacious drug praziquantel (PZQ) is the cornerstone of international efforts to control schistosomiasis as a public health problem. The success of such activities, in general, has in part led to a revision of WHO’s strategic plan and a vision for ‘a world free of schistosomiasis’, with elimination as a public health problem and complete interruption of transmission in selected regions by 2025.

Uganda was at the forefront of the treatment vanguard, first administering MDA in 2003. Amongst the communities first treated were those residing on the shores of Lake Albert, an area historically with high rates of periportal fibrosis. Our recent screens of school-children in these fishing communities show that despite concerted efforts and reported community treatment coverage rates of near 80%, infection intensities have remained extremely high and periportal fibrosis common, and potentially increasing, even amongst school-aged children.   There is therefore a major need for alternative strategies to understand the reason for, and intervene against, these major ‘hotspots’ of infection and morbidity if the ambitious aims of the WHO and the SDG 3: “Ensure healthy lives and promote wellbeing for all at all ages” are to be met.

For rapid uptake into national and international policy these interventions need to be built upon existing control structures and be logistically easy to facilitate. In lower transmission areas, MDA is targeted at school-children, combining the epidemiological knowledge that this age-group suffers the greatest burden of infection with easier implementation. This new programme will therefore examine the impact of increased PZQ treatment frequency within the school- structure, in addition to annual community MDA. At the core of this proposal is a superiority randomised intervention trial that asks the question: Does increased treatment frequency reduce the prevalence of childhood periportal fibrosis in hotspots of persistent schistosomiasis?

To elucidate the causes of high morbidity, in particular that distinguishing potential host from parasite, operational from biological, effects, we are incorporating a multidisciplinary range of analytical tools and measures, encompassing the host clinical, immunological and anthropological combined with parasite genomics and genetics, as well as statistical and mathematical analysis. Results will be disseminated to national, regional and international policy makers and to a multi- disciplinary NTD research community, while communication and open access data policies will ensure a wider reach.  Capacity is being built in NTD clinical trial infrastructure, alongside support in training young Ugandan researchers in the anthropological, genomic and immunological skills that will be essential to future clinical and observational studies on NTDs within Uganda and beyond.

fibro 1
Photo credit: Prof J.R. Stothard

Collaborators & Funders

 

 

 

See also

https://www.rvc.ac.uk/research/news/general/fibroschothttp://www.fibroschot.eu/

http://www.fibroschot.eu/

Advertisements